Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the sixteen research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have issued a buy rating on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $48.43.
A number of research firms have commented on TEVA. Zacks Research lowered Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. HC Wainwright reaffirmed a “buy” rating and set a $54.00 price target on shares of Teva Pharmaceutical Industries in a research report on Tuesday. Piper Sandler increased their price target on Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the stock an “overweight” rating in a research report on Thursday, November 12th. JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an “overweight” rating in a report on Monday, October 12th. Finally, Oppenheimer increased their price objective on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, October 9th.
Read Our Latest Research Report on TEVA
Insider Buying and Selling at Teva Pharmaceutical Industries
Institutional Trading of Teva Pharmaceutical Industries
Several institutional investors and hedge funds have recently modified their holdings of the business. Integrated Wealth Concepts LLC lifted its stake in shares of Teva Pharmaceutical Industries by 68.8% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,780 shares of the company’s stock valued at $783,000 after purchasing an additional 8,063 shares during the period. Allworth Financial LP lifted its position in shares of Teva Pharmaceutical Industries by 150.9% during the 3rd quarter. Allworth Financial LP now owns 3,202 shares of the company’s stock valued at $127,000 after buying an additional 1,926 shares in the last quarter. Quantessence Capital LLC acquired a new position in Teva Pharmaceutical Industries in the third quarter valued at about $734,000. Quantitative Investment Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth $228,000. Finally, Aspen Grove Capital LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth approximately $231,000. 54.05% of the stock is currently owned by institutional investors.
Key Stories Impacting Teva Pharmaceutical Industries
Here are a few of the latest stories about TEVA:
- Positive Sentiment: Argus raised its price target to $50 from $42 and reaffirmed a Buy rating, signaling confidence in Teva’s outlook. Argus raises Teva price target
- Neutral Sentiment: Teva reached a settlement in states’ generic-drug price-fixing litigation. The available report does not specify the settlement terms or financial impact, so the effect on the company’s liabilities is unclear. Settlement report
- Negative Sentiment: R&D chief medical officer Eric Hughes is leaving for another opportunity. David Gardiner will lead the transition while Teva searches for a successor, potentially raising concerns about continuity in a strategically important area. The company says its R&D priorities are unchanged and reiterated its goal of $6–7 billion in innovative-medicines revenue by 2030. Teva R&D leadership transition
Teva Pharmaceutical Industries Stock Down 1.0%
Shares of NYSE TEVA opened at $42.19 on Thursday. Teva Pharmaceutical Industries has a 12-month low of $24.01 and a 12-month high of $44.57. The firm has a market cap of $49.16 billion, a PE ratio of 98.11, a P/E/G ratio of 3.69 and a beta of 0.97. The company’s fifty day simple moving average is $40.51 and its 200 day simple moving average is $35.21. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 1.59.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. The firm had revenue of $4.39 billion for the quarter, compared to analyst estimates of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period last year, the company earned $0.78 EPS. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries will post 1.98 earnings per share for the current fiscal year.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.
See Also
- Five stocks we like better than Teva Pharmaceutical Industries
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
